Systematic analysis of secreted proteins reveals synergism between IL6 and other proteins in soft agar growth of MCF10A cells

Cell and Bioscience

Volumn 1, Issue 1, 2011, Pages

  Van Huffel, Sofie C ^a   Tham, Jill M ^a   Zhang, XiaoQian ^a   Lim, KohPang ^a   Yang, ChunXuan ^a   Tan, YikLoo ^a   Ong, Felicia ^a   Lee, Ian ^b   Hong, WanJin ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIA;

EID: 80052907500     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-1-13     Document Type: Article

References (38)

1. Lee FS, Lane TF, Kuo A, Shackleford GM, Leder P. Insertional mutagenesis identifies a member of the Wnt gene family as a candidate oncogene in the mammary epithelium of int-2/Fgf-3 transgenic mice. Proc Natl Acad Sci USA 1995, 92:2268-2272. 10.1073/pnas.92.6.2268, 42465, 7892260.
2. MacArthur CA, Shankar DB, Shackleford GM. Fgf-8, activated by proviral insertion, cooperates with the Wnt-1 transgene in murine mammary tumorigenesis. J Virol 1995, 69:2501-2507. 188926, 7884899.
3. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982, 31:99-109. 10.1016/0092-8674(82)90409-3, 6297757.
4. Peters G, Brookes S, Smith R, Dickson C. Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell 1983, 33:369-377. 10.1016/0092-8674(83)90418-X, 6305506.
5. Roelink H, Wagenaar E, Lopes da Silva S, Nusse R. Wnt-3, a gene activated by proviral insertion in mouse mammary tumors, is homologous to int-1/Wnt-1 and is normally expressed in mouse embryos and adult brain. Proc Natl Acad Sci USA 1990, 87:4519-4523. 10.1073/pnas.87.12.4519, 54147, 2162045.
6. Theodorou V, Boer M, Weigelt B, Jonkers J, van d V, Hilkens J. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene 2004, 23:6047-6055. 10.1038/sj.onc.1207816, 15208658.
7. Theodorou V, Kimm MA, Boer M, Wessels L, Theelen W, Jonkers J, Hilkens J. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet 2007, 39:759-769. 10.1038/ng2034, 17468756.
8. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988, 55:619-625. 10.1016/0092-8674(88)90220-6, 3180222.
9. Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J. Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Rep 2006, 15:179-185.
10. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002, 2:311-315. 10.3816/CBC.2002.n.008, 11899364.
11. Yokoe T, Iino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer 2000, 7:187-190. 10.1007/BF02967458, 11029796.
12. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003, 88:1721-1726. 10.1038/sj.bjc.6600956, 2377148, 12771987.
13. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon M. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001, 61:8851-8858.
14. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007, 117:3988-4002. 10.1172/JCI32533, 2096439, 18060036.
15. di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, Musiani P, Colombo MP, Ferrini S. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 2004, 172:1540-1547.
16. Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B, Weighardt H, Essler M. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 2006, 177:8266-8272.
17. Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, Sun KH. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 2009, 183:6217-6226. 10.4049/jimmunol.0901272, 19841177.
18. Zhu S, Lee DA, Li S. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 2010, 184:2348-2354. 10.4049/jimmunol.0902371, 2824785, 20139275.
19. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-4665. 2929399, 14581334.
20. Hashmi MH, Van Veldhuizen PJ. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther 2010, 10:807-817. 10.1517/14712598.2010.480971, 20384523.
21. Callahan R, Smith GH. Common integration sites for MMTV in viral induced mouse mammary tumors. J Mammary Gland Biol Neoplasia 2008, 13:309-321. 10.1007/s10911-008-9092-6, 18709449.
22. Katoh M. Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 2008, 33:233-237.
23. Zhang Y, Ma B, Fan Q. Mechanisms of breast cancer bone metastasis. Cancer Lett 2010, 292:1-7. 10.1016/j.canlet.2009.11.003, 20006425.
24. Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009, 66:9-26. 10.1007/s00018-008-8321-x, 18726069.
25. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 1994, 91:2156-2160. 10.1073/pnas.91.6.2156, 43329, 8134364.
26. Muleris M, Almeida A, Gerbault-Seureau M, Malfoy B, Dutrillaux B. Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique. Genes Chromosomes Cancer 1994, 10:160-170. 10.1002/gcc.2870100303, 7522038.
27. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006, 7:167-174. 10.1016/S1470-2045(06)70579-4, 16455481.
28. Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci USA 2008, 105:12780-12784. 10.1073/pnas.0805865105, 2529096, 18711144.
29. Stevens VL, Rodriguez C, Pavluck AL, Thun MJ, Calle EE. Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2006, 15:1226-1228. 10.1158/1055-9965.EPI-05-0930, 16775186.
30. Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, Helzlsouer KJ. Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev 2007, 31:95-101. 10.1016/j.cdp.2007.02.004, 17428620.
31. Gouedard C, Barouki R, Morel Y. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler Thromb Vasc Biol 2004, 24:2378-2383. 10.1161/01.ATV.0000146530.24736.ce, 15458977.
32. Ogawa K, Tanaka K, Ishii A, Nakamura Y, Kondo S, Sugamura K, Takano S, Nakamura M, Nagata K. A novel serum protein that is selectively produced by cytotoxic lymphocytes. J Immunol 2001, 166:6404-6412.
33. Yamanaka R, Arao T, Yajima N, Tsuchiya N, Homma J, Tanaka R, Sano M, Oide A, Sekijima M, Nishio K. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 2006, 25:5994-6002. 10.1038/sj.onc.1209585, 16652150.
34. Tsuji H, Okamoto K, Matsuzaka Y, Iizuka H, Tamiya G, Inoko H. SLURP-2, a novel member of the human Ly-6 superfamily that is up-regulated in psoriasis vulgaris. Genomics 2003, 81:26-33. 10.1016/S0888-7543(02)00025-3, 12573258.
35. Lee JW, Lee YS, Yoo KH, Lee KH, Park K, Ahn T, Ko C, Park JH. LY-6K gene: a novel molecular marker for human breast cancer. Oncol Rep 2006, 16:1211-1214.
36. Annunziata I, Bouche V, Lombardi A, Settembre C, Ballabio A. Multiple sulfatase deficiency is due to hypomorphic mutations of the SUMF1 gene. Hum Mutat 2007, 28:928. 10.1002/humu.9504, 17657823.
37. Shackleford GM, MacArthur CA, Kwan HC, Varmus HE. Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt-1 transgenic mice by insertional activation of int-2/Fgf-3 and hst/Fgf-4. Proc Natl Acad Sci USA 1993, 90:740-744. 10.1073/pnas.90.2.740, 45741, 8380647.
38. Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 2008, 7:231-240. 10.1038/nrd2482, 18259184.